Proliferation and apoptosis property of mesenchymal stem cells derived from peripheral blood under the culture conditions of hypoxia and serum deprivation

Chinese Medical Journal

Volumn 124, Issue 23, 2011, Pages 3959-3967

  Fu, Wei Li ^a   Jia, Zhu Qing ^b   Wang, Wei Ping ^b   Zhang, Ji Ying ^a   Fu, Xin ^a   Duan, Xiao Ning ^a   Leung, Kevin Kar Ming ^a   Zhou, Chun Yan ^b   Yu, Jia Kuo ^a  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Apoptosis; Hypoxia; Mesenchymal stem cells derived from peripheral blood; Proliferation; Serum deprivation

Indexed keywords

BETA1 INTEGRIN; CD45 ANTIGEN; CELL MARKER; CHOLECYSTOKININ OCTAPEPTIDE; DNA NUCLEOTIDYLEXOTRANSFERASE; GRANULOCYTE COLONY STIMULATING FACTOR; HERMES ANTIGEN; LIPOCORTIN 5; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PLERIXAFOR;

ADIPOCYTE MEMBRANE; ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CARTILAGE CELL; CELL ADHESION; CELL DIFFERENTIATION; CELL HYPOXIA; CELL PROLIFERATION; CELL SHAPE; CELL STRUCTURE; CELL SURFACE; CONTROLLED STUDY; EXPERIMENTAL RABBIT; HEMATOPOIETIC STEM CELL; HEMOLYSIS; IN VITRO STUDY; MESENCHYMAL STEM CELL; NONHUMAN; OSTEOBLAST; OXYGEN TENSION; PERIPHERAL BLOOD STEM CELL; PHENOTYPIC VARIATION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; STEM CELL MOBILIZATION; TISSUE REPAIR;

ANIMALS; APOPTOSIS; CELL HYPOXIA; CELL PROLIFERATION; CELLS, CULTURED; IN SITU NICK-END LABELING; MESENCHYMAL STEM CELLS; RABBITS;

EID: 84862974144     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2011.23.022     Document Type: Article

References (30)

1. Bianco P, Robey PG, Simmons PJ. Mesenchymal stem cells: Revisiting history, concepts, and assays. Cell Stem Cell 2008; 2: 313-319.
2. Tan JM, Wang J, Liao LM. Mesenchymal-stem-cell-based experimental and clinical trials: current status and open questions. Expert Opin Biol Th 2011; 11: 893-909.
3. Kassem M, Abdallah BM. Human mesenchymal stem cells: from basic biology to clinical applications. Gene Ther 2008; 15: 109-116.
4. Giordano A, Galderisi U, Marino IR. From the laboratory bench to the patient's bedside: an update on clinical trials with mesenchymal stem cells. J Cell Physiol 2007; 211: 27-35.
5. Hauzeur JP, Gangji V. Phases 1-3 Clinical trials using adult stem cells in osteonecrosis and nonunion fractures. Stem Cells Int 2010; 2010: 1-4.
6. Cao FJ, Feng SQ. Human umbilical cord mesenchymal stem cells and the treatment of spinal cord injury. Chin Med J 2009; 122: 225-231.
7. Ma L, Feng XY, Cui BL, Law F, Jiang XW, Yang LY, et al. Human umbilical cord Wharton's Jelly-derived mesenchymal stem cells differentiation into nerve-like cells. Chin Med J 2005; 118: 1987-1993.
8. van Osch GJVM, Brittberg M, Dennis JE, Bastiaansen-Jenniskens YM, Erben RG, Konttinen YT, et al. Cartilage repair: past and future - lessons for regenerative medicine. J Cell Mol Med 2009; 13: 792-810.
9. Wakitani S, Matsumoto T, Okabe T, Ikawa T, Iida T, Yasuda H, et al. Articular cartilage repair with autologous bone marrow mesenchymal cells. J Cell Physiol 2010; 225: 291-295.
10. Toma C, Pittenger MF, Cahill KS, Byrne BJ, Kessler PD. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation 2002; 105: 93-98.
11. Sung JH, Lee EY, Xia Y, Kim WS, Kim MH, Kim TH, et al. Hypoxia-enhanced wound-healing function of adiposederived stem cells: Increase in stem cell proliferation and up-regulation of VEGF and bFGF. Wound Repair Regen 2009; 17: 540-547.
12. Petite H, Potier E, Ferreira E, Meunier A, Sedel L, Logeart-Avramoglou D. Prolonged hypoxia concomitant with serum deprivation induces massive human mesenchymal stem cell death. Tissue Eng 2007; 13: 1325-1331.
13. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini FC, Krause DS, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8: 315-317.
14. Horwitz EM, Le Blanc K, Dominici M, Mueller I, Slaper-Cortenbach I, Marini FC, et al. Clarification of the nomenclature for MSC: The international society for cellular therapy position statement. Cytotherapy 2005; 7: 393-395.
15. Wang HW, Lin LM, He HY, You F, Li WZ, Huang TH, et al. Human umbilical cord mesenchymal stem cells derived from Wharton's jelly differentiate into insulin-producing cells in vitro. Chin Med J 2011; 124: 1534-1539.
16. Zhang Y, Li CD, Jiang XX, Li HL, Tang PH, Mao N. Comparison of mesenchymal stem cells from human placenta and bone marrow. Chin Med J 2004; 117: 882-887.
17. Roufosse CA, Direkze NC, Otto WR, Wright NA. Circulating mesenchymal stem cells. Int J Biochem Cell B 2004; 36: 585-597.
18. Lund TC, Tolar J, Orchard PJ. Granulocyte colony-stimulating factor mobilized CFU-F can be found in the peripheral blood but have limited expansion potential. Haematologica 2008; 93: 908-912.
19. Fruehauf S, Veldwijk MR, Seeger T, Schubert M, Laufs S, Topaly J, et al. A combination of granulocyte-colonystimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European phase II study. Cytotherapy 2009; 11: 992-1001.
20. Vavken P, Samartzis D. Effectiveness of autologous chondrocyte implantation in cartilage repair of the knee: a systematic review of controlled trials. Osteoarthritis Cartilage 2010; 18: 857-863.
21. Curl WW, Krome J, Gordon ES, Rushing J, Smith BP, Poehling GG. Cartilage injuries: A review of 31,516 knee arthroscopies. Arthroscopy 1997; 13: 456-460.
22. Cabral JMS, Dos Santos F, Andrade PZ, Boura JS, Abecasis MM, Da Silva CL. Ex vivo expansion of human mesenchymal stem cells: a more effective cell proliferation kinetics and metabolism under hypoxia. J Cell Physiol 2010; 223: 27-35.
23. Ma T, Grayson WL, Zhao F, Bunnell B. Hypoxia enhances proliferation and tissue formation of human mesenchymal stem cells. Biochem Bioph Res Commun 2007; 358: 948-953.
24. Bonavita F, Stefanelli C, Giordano E, Columbaro M, Facchini A, Bonafe F, et al. H9c2 cardiac myoblasts undergo apoptosis in a model of ischemia consisting of serum deprivation and hypoxia: inhibition by PMA. FEBS Lett 2003; 536: 85-91.
25. Chen X, Zhu WQ, Chen JH, Cong XF, Hu SS. Hypoxia and serum deprivation-induced apoptosis in mesenchymal stem cells. Stem Cells 2006; 24: 416-425.
26. Dai JW, Zhao YH, Wang B, Gao Y, Zhao YN, Xiao ZF, et al. Olfactory ensheathing cell apoptosis induced by hypoxia and serum deprivation. Neurosci Lett 2007; 421: 197-202.
27. Chen J, Baydoun AR, Xu R, Deng L, Liu X, Zhu W, et al. Lysophosphatidic acid protects mesenchymal stem cells against hypoxia and serum deprivation-induced apoptosis. Stem Cells 2008; 26: 135-145.
28. Muller I, Holzwarth C, Vaegler M, Gieseke F, Pfister SM, Handgretinger R, et al. Low physiologic oxygen tensions reduce proliferation and differentiation of human multipotent mesenchymal stromal cells. BMC Cell Biol 2010; 11.
29. Wang DW, Fermor B, Gimble JM, Awad HA, Guilak F. Influence of oxygen on the proliferation and metabolism of adipose derived adult stem cells. J Cell Physiol 2005; 204: 184-191.
30. Baek JH, Jang JE, Kang CM, Chung HY, Kim ND, Kim KW. Hypoxia-induced VEGF enhances tumor survivability via suppression of serum deprivation-induced apoptosis. Oncogene 2000; 19: 4621-4631.